Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
2.23
+0.12 (+5.69%)
Latest market quote · 2026-09-22 20:00 (UTC)
Company profile
Healthcare
Drug Manufacturers - Specialty & Generic
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Company websiteIssued common shares
Shares available to trade
Price relative to forecast earnings
Sensitivity relative to the market
Mean published price target
Reported full-time workforce
Shares held by institutions
Shares held by company insiders
Current session activity
High-to-low move
Share of advancing days
Based on daily returns
Versus provisional U.S. equity benchmark
Annualized negative-return risk
Historical one-day loss threshold
Latest coverage
GuruFocus.com · Sep 23, 2026
Zacks · Sep 22, 2026
ACCESS Newswire · Sep 22, 2026
ACCESS Newswire · Sep 16, 2026
Reader research
Join the discussion
Log in to share sentiment, a price target, and your investment thesis.
Log in to commentLargest one-day advance
Largest one-day decline
Largest one-year decline
Low-to-high range position
Shares sold short
Percent of public float
Short-interest ratio
Nearest-expiry open interest
Price, momentum, breadth and range
Scores are technical indicators derived from the available one-year price history and are not investment recommendations. Short-interest and options figures display when supplied by the market-data provider.
Zacks · Sep 14, 2026